Raymond James Financial Services Advisors Inc. raised its stake in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 26.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 142,930 shares of the company’s stock after purchasing an additional 30,030 shares during the quarter. Raymond James Financial Services Advisors Inc. owned 0.07% of TherapeuticsMD worth $756,000 at the end of the most recent reporting period.
Other hedge funds also recently made changes to their positions in the company. Schwab Charles Investment Management Inc. raised its holdings in shares of TherapeuticsMD by 10.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 694,167 shares of the company’s stock worth $3,659,000 after acquiring an additional 67,855 shares during the last quarter. Stifel Financial Corp boosted its position in shares of TherapeuticsMD by 377.9% in the second quarter. Stifel Financial Corp now owns 2,052,030 shares of the company’s stock worth $10,820,000 after buying an additional 1,622,668 shares during the period. State Street Corp boosted its position in shares of TherapeuticsMD by 14.9% in the second quarter. State Street Corp now owns 4,486,585 shares of the company’s stock worth $23,647,000 after buying an additional 583,094 shares during the period. Vanguard Group Inc. boosted its position in shares of TherapeuticsMD by 4.4% in the second quarter. Vanguard Group Inc. now owns 10,231,081 shares of the company’s stock worth $53,918,000 after buying an additional 429,211 shares during the period. Finally, Bamco Inc. NY boosted its position in shares of TherapeuticsMD by 126.8% in the second quarter. Bamco Inc. NY now owns 850,000 shares of the company’s stock worth $4,479,000 after buying an additional 475,200 shares during the period. Institutional investors own 73.76% of the company’s stock.
Shares of TherapeuticsMD, Inc. (NASDAQ TXMD) opened at $6.80 on Wednesday. TherapeuticsMD, Inc. has a one year low of $3.50 and a one year high of $8.30.
TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Monday, November 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.03. The firm had revenue of $4.42 million for the quarter, compared to analysts’ expectations of $5.36 million. TherapeuticsMD had a negative return on equity of 65.16% and a negative net margin of 457.00%. TherapeuticsMD’s revenue for the quarter was down 19.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.13) earnings per share. equities analysts expect that TherapeuticsMD, Inc. will post -0.37 EPS for the current year.
Several equities research analysts have recently weighed in on the company. Morgan Stanley initiated coverage on TherapeuticsMD in a research report on Friday, September 8th. They issued an “equal weight” rating and a $6.00 target price for the company. BidaskClub raised TherapeuticsMD from a “hold” rating to a “buy” rating in a report on Friday, September 8th. Jefferies Group reissued a “buy” rating and issued a $15.00 price target on shares of TherapeuticsMD in a report on Friday, September 8th. Deutsche Bank reissued a “buy” rating and issued a $10.00 price target on shares of TherapeuticsMD in a report on Wednesday, September 13th. Finally, Cowen reissued an “outperform” rating and issued a $16.00 price target (up previously from $13.00) on shares of TherapeuticsMD in a report on Monday, November 6th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $15.00.
In related news, Director Tommy G. Thompson purchased 5,000 shares of the company’s stock in a transaction dated Friday, December 8th. The shares were acquired at an average cost of $6.21 per share, for a total transaction of $31,050.00. Following the transaction, the director now owns 3,555 shares of the company’s stock, valued at $22,076.55. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 23.92% of the stock is currently owned by corporate insiders.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.